Cannabis 3.0 Closing the Medical Cannabis Value Chain Loop- From Growing, Extraction, Manufacturing and Retail to Patient Efficacy

Although the benefits of cannabis have been known for years, it has only recently grabbed the attention of the medical community through the medium of government regulators and policies. However, due to the ephemeral nature of plants, and the creeping scope of need for more research and governmental regulations, there is still much to learn about cannabis and its medicinal benefits.

To date, we know only a small percentage of the effects the cannabis strain has on the human body. Cannabis is a complex plant and like every plant, or any living organism, it is unique. Despite advanced consumer feedback, there are still many unknown variables associated with the plant and the results. Due to certain constraints, including the inability to break down the plant and identify the active pharmaceutical ingredients used to rebuild specific products, regulators like the Federal Drug Administration (FDA), have delayed the approval of current medicinal products.

Cannabis 1.0, 2.0, and 3.0 refers to the evolutionary phases of the cannabis industry and is a good roadmap to follow to arrive at where we are today. Most recently, researching cannabis as a medicinal product has been greatly influenced by cutting edge technologies like artificial intelligence (machine learning algorithms), blockchain (data storage), regulatory technologies, and manufacturing & consumer input devices (data gathering). This “big data” system combines all of these technologies to create an output of reliable information through a unique path, one that can be confidentially used by all industry stakeholders like consumers, doctors, manufacturers, regulators.

However, to arrive at where we are now, we must recap the journey, starting from the beginning. Cannabis 1.0, also commonly referred to as medical marijuana in its beginning phase, went through a series of legislative changes in many jurisdictions. Most notable, it was removed from the Schedule 1 list, and the growth and sale of medical marijuana and its hemp-derived products became legalized in many places.

The battle to legalize and benefit from the use of cannabis as medical marijuana seemed to be over, however truth be told the war had just begun but on a larger, more global scale. After , measurements of different strains of cannabis in various jurisdictions begun to affect policy, which resulted in the need for further research on dosage, the efficacy of specific strains and products, manufacturing, and growing requirements.

As a result, the beginning of a new era spawned within the medical marijuana industry. Business plans for licensing and growing cannabis became less attractive to some investors, and the need for controlled processes was imposed as part of the regulated process for industry.

Cannabis 2.0 marked the continued evolutionary phase of medical marijuana. International standardization for growing, extraction, manufacturing, and tracing of the product from the origin to the point of sale occurred during this phase. In addition, many of the original 2.0 companies continued to focus only on the tracking and growing of the product, right up to the wholesale distributor or manufacturer end product.

However, in the Cannabis 2.0+ phase, companies like Global Cannabis Application Corp (CSE: APP) decided to trace the effects beyond the point of sale and wholesale distribution to user efficacy tracking. This was done with the help of biometrics and artificial intelligence (machine learning). And once the data was obtained, computing the efficacy and experience of the user was reported back to the pharmacy, doctors, policy makers, regulators, and growers.

Global Cannabis Application Corp’s ability to track patient efficacy helped bridge the gap in the next evolutionary phase, Cannabis 3.0.

A holistic solution is required to track efficacy from edibles, vapes, tinctures, skin lotions, flowers, coffees, water, pills, beer, soda, wine, fruit juices, spirits, and sports drinks since the cannabis variety is becoming more abundant in the marketplace.

Cannabis 3.0, the latest phase, is where technology meets efficacy in the cannabis world.  Form policy, real-time data, and future clinical trials will help define various medicinal brands, products, including the effectiveness of the “brands” products when treating patients.

Using big data and machine learning solutions, like GCAC’s Citizen Green Prescriptii Patient Care Solution, draws the data and effectiveness of a strain and the “brand” of product being used by a patient. This allows them to discern between ones that are effective and the ones that are considered “gimmicks” touting the benefits of cannabis, hemp, or CBD to attract the consumer but that lack the effective ingredients.

The Cannabis 3.0 phase was designed to increase the competency of the products that are highly ranked by patients based on their feedback and support in the form of tangible and measurable data.

Cannabis 3.0 is where individual opinions, biometric tracking, and tracing of the product from its origin meet brand recognition of these products in the marketplace. Therefore, we will have the answers when someone asks, who has the best strain of medical cannabis? Who has the best CBD oil for headaches, knees, joint pain, or anxiety? Individuals will have the ability to verify real-time data, opinions, and other facts about the market. Brand efficacy can create two streams of deliverables; for example, mass producers of gummy edibles can serve one kind of benefit to a mass of people, and on a smaller scale manufacturing that measures custom needs and is tailored on a more individual basis can serve more individualistic needs.

Being able to trace the efficacy from how the products are being made, to what ailment they are assisting, and its effectiveness in treating the patient will reinforce consumers’ trust in the market. Cannabis 3.0 is a vital phase of the cannabis evolution because doctors will have the ability to view real-time data and therefore make real-time recommendations based on quantitative and qualitative information on users and the proper delivery of patient care and consumer protection.

What does this mean to you as a patient? Well, you will be able to inform yourself before going to a pharmacy. How? You can consult your personalized Citizen Green app and review the brands or strains that are recommended for you, including how they fit your own treatment journey, and its expected effects, based on your biometrics, medical history, and medications, from your home province, state, or continent. The result is a more reliable and effective personalized treatment.

It is the ultimate experience in consumer brand recognition, patient care and efficacy, and consumer protection. Cannabis 3.0 will bring about changes in regulatory policies on how products are marketed on shelves based on real-time data and its efficacy.

Cannabis 3.0 will also assist in benefitting the market with a higher quality of product while generating trusted “household” brands in a previous market that was demonized for generations. It will help increase reliability and restore peoples’ trust in doctors writing prescriptions using brand and strain specific information based on real-time data and clinical information.

As recognized as the “AI of the Year” at the prestigious Malta Medical CannaBiz World Summit in November 2019, GCAC is a pioneer of not just technology, but also cannabis data workflow. We provide an ecosystem that secures supply chains from seed to sale to seed for uniquely labeled or uniquely identifiable cannabis products, helping resolve distortions in medical prognosis, creating confidence in prescribing medical cannabis for aliment treatment.

Best A.I of the year 2019